Who are Indenol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ProAir, Lopressor, Eraldin, Beta Blockers Carvedilol Phosphate, Carvedilol CR, Arotinolol Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indenol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Indenol — Competitive Intelligence Brief

Indenol (Indenol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

discontinued Beta-1 adrenergic receptor, Beta-2 adrenergic receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Indenol (Indenol) — Yong Seog Oh.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Indenol TARGET	Indenol	Yong Seog Oh	discontinued		Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
ProAir	albuterol	Generic (originally Allen & Hanburys/GSK)	marketed	SABA (Short-acting beta-2 agonist)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor	1982-05-05
Lopressor	metoprolol	Generic (originally Ciba-Geigy/Novartis)	marketed	Beta-1 selective blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A	1978-08-07
Eraldin	PRACTOLOL		marketed	practolol	Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Beta Blockers Carvedilol Phosphate	Beta Blockers Carvedilol Phosphate	Seoul National University Hospital	marketed	Beta blocker (non-selective, with alpha-1 blocking activity)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Carvedilol CR	Carvedilol CR	University of Florida	marketed	Non-selective beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Arotinolol Hydrochloride	Arotinolol Hydrochloride	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Indenol — Competitive Intelligence Brief. https://druglandscape.com/ci/indenol. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab